LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES

7 CEVENFACTA

Pharmaceutical products; medicine; injectable pharmaceutical preparations; therapeutic proteins for the treatment of coagulation disorders;

ACTSEVEN

Pharmaceutical preparations, medicines, injectable pharmaceutical preparations, therapeutic proteins for the treatment of coagulation disorders;ACT SEVEN;Color is not claimed as a feature of the mark.;

APTAPURE

Contaminant removal services for the purpose of purification of chemical or biological compounds of interest; contaminant removal services for the purpose of purification of pharmaceutical compounds;Medicines and pharmaceutical preparations obtained by means of a purification process using aptamers for use in the treatment of hemophilia, immunology, infectious diseases, neuropathology, and oncology; medicines and pharmaceutical preparations containing a purified protein of interest obtained by separation of integral forms from truncated forms for use in the treatment of hemophilia, immunology, infectious diseases, neuropathology, and oncology; medicines and pharmaceutical preparations containing a purified protein of interest obtained by separation of forms modified by post-translational modification of unmodified or differently modified forms for use in the treatment of hemophilia, immunology, infectious diseases, neuropathology, and oncology; medicines and pharmaceutical preparations containing a purified protein of interest obtained by separation of active forms from inactive forms for use in the treatment of hemophilia, immunology, infectious diseases, neuropathology, and oncology;APTAPURE; APTAMERS PURE;

AQTISEVEN

Pharmaceutical preparations, medicines, injectable pharmaceutical preparations, therapeutic proteins for the treatment of coagulation disorders;AQTI SEVEN;

CLAIRYG

Polyvalent human immunoglobulin to be administered parenterally, subcutaneously or intravenously, by health care workers in hospitals and clinics, in outpatient clinics and during external consultations, in medical practices and by self-administration for the treatment of congenital or acquired immunodeficiencies or to provide immunomodulation;

CLOTTAFACT

Pharmaceutical products and preparations and in particular blood proteins of natural or transgenic, synthetic or semi-synthetic origin;

CLOTTAFAST

Pharmaceutical products and preparations for use in the treatment of inherited and acquired fibrinogen deficit; blood proteins of natural or transgenic, synthetic or semi-synthetic origin for use in the treatment of inherited and acquired fibrinogen deficit;

COAGSEVEN

Pharmaceutical preparations for the treatment of bleeding disorders; drugs, namely, haemostatic pharmaceutical preparations for human use; injectable pharmaceutical preparations for the treatment of bleeding disorders; therapeutic proteins for the treatment of bleeding disorders;COAG SEVEN;

DABPLATE

Pharmaceutical preparations in the nature of monoclonal recombinant anti-rhesus D antibodies for the prevention of RhD alloimmunization in RhD-negative women carrying a RhD-positive fetus;DAB PLATE;The wording DABPLATE has no meaning in a foreign language.;

DMATRIA

Pharmaceutical preparations in the nature of monoclonal recombinant anti-rhesus D antibodies for the prevention of RhD alloimmunization in RhD-negative women carrying a RhD-positive fetus;The wording DMATRIA has no meaning in a foreign language.;

FIBCLOT

Pharmaceutical products and preparations for use in the treatment of inherited and acquired fibrinogen deficit; blood proteins naturally occurring or of transgenic origin, or synthetic or semi-synthetic preparations for therapeutic use; injectable pharmaceuticals for use in the treatment of inherited and acquired fibrinogen deficit;FIB CLOT;

FIBCLOT

Pharmaceutical products and preparations; blood proteins naturally occurring or of transgenic, synthetic or semi-synthetic origin; injectable pharmaceutical preparations;FIB CLOT;

HEMOLEVEN

Protein concentrates of human blood origin, for use in treating blood coagulation Factor XI deficiencies;Printed matter, namely, pamphlets, catalogs, newspapers, booklets, periodicals, books, reports on clinical studies, informational letters, and journals, all of the foregoing in the field of protein concentrates of human blood origin;Color is not claimed as a feature of the mark.;

HUMABFC

Pharmaceutical products and preparations for the treatment of cancer, autoimmune disorders, inflammatory disorders, viral and bacterial infections, blood diseases; medicines for cancer, autoimmune disorders, inflammatory disorders, viral and bacterial infections, blood diseases; protein supplements; diagnostic kits consisting primarily of monoclonal antibodies and fragment crystallizable proteins, buffers, and reagents for use in disease testing;Scientific and technological services, namely, scientific research and analysis in the field of monoclonal antibodies and fragment crystallizable proteins; design and development of medical products, namely, pharmaceutical compositions of monoclonal antibodies and fragment crystallizable proteins; scientific study and research in the field of the prevention and the treatment of cancer, autoimmune disorders, inflammatory disorders, viral and bacterial infections, blood diseases; research and development in the field of the prevention and the treatment of cancer, autoimmune disorders, inflammatory disorders, viral and bacterial infections, blood diseases; cellular and molecular biological research; testing, inspection or research of pharmaceuticals; medical and scientific research, namely, conducting clinical trials for others; consulting in the field of medical research; engineering; genetic engineering; scientific research services using protein expression platform technology for research and development of pharmaceuticals; scientific research services using protein expression platform technology for manufacturing protein-based therapeutics; medical and scientific research of recombinant protein platform technologies designed to lead to new human vaccines, therapeutic proteins and antibodies; scientific laboratory services in the field of monoclonal antibodies;

IQYMUNE

Pharmaceutical products; injectable pharmaceutical products; immunoglobulins; injectable immunoglobulins;

LFB

Editing and publishing of texts other than advertising texts in the field of health; arranging and providing education, training and instruction, namely, providing classes, seminars, symposiums, congresses, conferences, meetings, educational courses, and workshops in the field of health; organization and conducting of seminars, symposiums, congresses, conferences, meetings, educational courses, and workshops, in the field of health;Scientific apparatus and instruments, namely, diagnostic apparatus and instruments for calculating and managing drug penetration parameters, for assessing immune deficiency, for laboratory use; downloadable electronic and digital publications, namely, magazines, newsletters, brochures, articles in the field of health; downloadable instructional and teaching material, namely, software in the field of health; electronic reports featuring results from clinical trials and studies in the field of health; recorded software, namely, software for providing medical information in the field of immunology, haemostasis, intensive care, immune deficiency; computer software for educational and commercial activities, namely, software providing information in the field of health; software applications used with medical diagnostic apparatus to calculate and manage immune deficiency or bleeding; computer software for Websites, Intranet and the Internet, namely, software for training and information of patients and health professionals; downloadable computer software applications in the field of health for calculating and managing drug penetration parameters in the human body;Pharmaceutical and veterinary products and preparations for the treatment of disorders or diseases in the field of immunology, haemostasis, intensive care; medicines for the treatment of disorders or diseases in the field of immunology, haemostasis, intensive care; diagnostic products for medical and veterinary use for the treatment of disorders or diseases in the field of immunology, haemostasis, intensive care;Retail store services featuring pharmaceutical preparations and products, and medical devices; wholesale retail store services featuring pharmaceutical preparations and products, and medical devices; import and export agencies in the field of pharmaceutical preparations and products, and medical devices; commercial representation, namely, promoting the goods and services of others; sales promotion;Medical analysis relating to human blood plasma; sampling, collection and preservation of human blood plasma; providing advice and information in the field of health;Medical, veterinary, surgical apparatus and instruments, namely, diagnostic apparatus and instruments in the nature of apparatus for medical diagnostic testing and screening in the field of immunology, haemostasis, intensive care, immune deficiency; apparatus for analysis and diagnosis of disorders or diseases in the field of immunology, haemostasis, intensive care, immune deficiency; medical devices, namely, blood collection kits, disposable cartridge, diagnostic kits consisting primarily of probes, buffers and reagents for use in blood coagulation testing and screening;Scientific and technological services as well as research and design services relating thereto, namely, scientific research, product development, design and testing for new product and engineering in the field of health; industrial analysis and research services in the field of health; scientific research services using protein expression platform technology for research and development of pharmaceuticals; scientific research services using protein expression platform technology for manufacturing protein-based therapeutics; medical and scientific research of recombinant protein platform technologies designed to lead to new human vaccines; conducting scientific studies in the field of immunology, haemostasis, intensive care; research and development of new products for others; scientific research for medical purposes in the field of immunology, haemostasis, intensive care; cellular and molecular biology research; testing of pharmaceutical products; conducting clinical trials for others in the field of immunology, haemostasis, intensive care; engineering; advice and assistance in the field of health;

LFB PLASMA

The mark consists of three co-linear rectangles, with the left rectangle being gray, the middle rectangle being red, and the right rectangle being blue. The letters LFB are gray and are positioned to the right of the three rectangles. The letter B in LFB is italicized. The word PLASMA is gray and is positioned immediately beneath the letters LFB.;The colors gray, red and blue are claimed as a feature of the mark.;Medical services, namely, blood component collection services;PLASMA;